Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | JAK1 F805V |
| Gene Variant Detail | |
| Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK1 Inhibitor JAK1 Inhibitor - ATP competitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| JAK1 F805V | hematologic cancer | sensitive | JAK1 Inhibitor - ATP competitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 phosphorylation and viability in a cell line expressing JAK1 F805V in culture (PMID: 36786170). | 36786170 |